Search
Search Results
##search.searchResults.foundPlural##
-
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2561PDF: 821HTML: 1746 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2287PDF: 1838HTML: 838 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2318PDF: 851HTML: 1697Figure 1: 224Table 1: 236 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3316PDF: 967HTML: 3147 -
-
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1359PDF: 1083HTML: 427 -
-
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2930PDF: 1052HTML: 5641 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2748PDF: 791HTML: 2324 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1489HTML: 642PDF: 879 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1480PDF: 961HTML: 253 -
ASSOCIATION OF BASELINE PLATELET COUNT WITH COMPLETE REMISSION, SEVERE BLEEDING, AND 24-MONTH OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
66PDF: 41Suppl. Files: 7Html: 8Html Suppl. Files: 7 -
-
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3398PDF: 989HTML: 2991 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1658PDF: 1104HTML: 478 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3719PDF: 2600HTML: 1625 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
762PDF: 482HTML: 6281 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1355PDF: 615HTML: 4149 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2653PDF: 977HTML: 593 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1947PDF: 1042HTML: 246 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2075PDF: 868HTML: 257 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1359PDF: 947HTML: 337 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4473PDF: 1800HTML: 1122 -
TUBERCULOSIS IN TROPICAL AREAS AND IMMIGRANTS
3455PDF: 1370HTML: 6344 -
Allogeneic transplantation in patients with advanced systemic mastocytosis: case report of a single center experience Allogeneic Transplantation in Systemic Mastocytosis
2105PDF: 123HTML: 32 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3357PDF: 1751HTML: 1166
1 - 44 of 44 items







